Trial Profile
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, added to metformin and sulphonylurea in patients with type 2 diabetes (T2DM).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2017
Price :
$35
*
At a glance
- Drugs Gemigliptin (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TROICA
- 26 Oct 2017 New trial record